Executive chairman song Ruilin and vice chairman Liu Dianbo visited Boston Consulting (Japan) and other research institutions

Source: China pharmaceutical innovation promotion association was invited to attend the Sixth Asia partnership conference of Pharmaceutical Associations on April 5, 2017 in Tokyo, Japan, Song Ruilin, executive chairman of APAC, and Liu Dianbo, vice chairman and executive chairman of green leaf Pharmaceutical Group, visited Boston Consulting Japan and Japan Institute of health and global policy and other relevant departments on relevant Japanese pharmaceutical policies On the morning of April 7, song Ruilin, executive chairman, Liu Dianbo and his delegation visited Boston Consulting and Research Institute, and were warmly received by senior partner and managing director of Boston Consulting Japan, Mr Tsukuba and other members Mr Zhi Cao made a detailed introduction to Japan's medical and health system and the ecological environment of the pharmaceutical industry He pointed out that Japan has formulated a number of policies to promote pharmaceutical innovation, and has given appropriate policy tolerance to the price of patented drugs within the patent period, so as to ensure the rational and predictable benefits of patented drugs In addition, he has set up acceleration links in the drug examination and approval system, so as to provide for the early listing of patented drugs At the same time, Japan's Ministry of health, labor and welfare, as a country with a national medical security system, has made greater efforts to promote the use of generic drugs, including the proportion of the use of generic drugs in the national plan, requiring pharmacists to regulate generic drugs for patients and curb the growth of medical costs During the discussion, experts reached a consensus that Japan's pharmaceutical industry has made remarkable progress in recent 20 years, especially in innovative medicine The main reasons include: first, opening up the door to welcome international innovative drugs into Japan; second, reforming the review policy to improve the review efficiency and shorten the review time; and finally, implementing inclusive and rational innovative drug prices Case policy Song Ruilin, executive chairman, pointed out that at present, the Chinese government attaches great importance to pharmaceutical innovation and development, and there are many lessons to be learned from the experience of Japanese pharmaceutical innovation and development As a social group committed to promoting the innovation and development of Chinese medicine, China pharmaceutical promotion association will continue to have a deep understanding of relevant Japanese policies and promote cooperation and exchanges between the two sides From April 6 to 7, song Ruilin, executive chairman, Liu Dianbo and his delegation also visited Japan's Institute of health and global policy, CIMIC, TMI law firm, the largest pharmaceutical cro company in Japan, and other relevant institutions to have in-depth understanding of Japan's medical security system, pharmaceutical intellectual property rights and related pharmaceutical administration and other issues.